Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $77.7 million versus the consensus estimate of $75.29 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2026 revenue of $315-325 million, versus the consensus of $326.2 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.